Stocks
Athira Pharma, Inc.ATHA
NASDAQHealthcareBiotechnology$6.75-6.12%
Focused on developing small molecule therapeutics for neurodegenerative diseases, this biotech firm targets conditions like Alzheimer's and Parkinson's. Investors monitor its clinical-stage pipeline, particularly lead candidate fosgonimeton, which recently faced clinical trial setbacks impacting its valuation.
Market Cap: $26.6M52W Range: $2.20 – $8.36
Congressional Interest in Athira Pharma, Inc. (ATHA)
1 member of Congress has disclosed 3 trades in Athira Pharma, Inc. (ATHA), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
1
Buys
2
Sells
1
Who in Congress Is Trading ATHA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |